GlassScriptPhysician profile
Lacey D Spohn
NPI 1730607599
$1,716.50
in general payments reported to CMS, 2019-2025
22 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $505 · 2022: $296 · 2023: $408 · 2024: $359 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $421.39 | 2021-2025 | Repatha, Otezla, Prolia |
| Abbvie INC. | $273.48 | 2021-2023 | |
| Lilly USA, LLC | $124.16 | 2021-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $118.26 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $115.59 | 2021-2025 | Airsupra, Flumist Quadrivalent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.84 | 2021-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $83.46 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $75.57 | 2021-2022 | |
| Exact Sciences Corporation | $55.95 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $51.03 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.77 | 2025 | Caplyta |
| Organogenesis INC. | $40.30 | 2024 | Puraply Am |
| Novartis Pharmaceuticals Corporation | $33.60 | 2022-2025 | |
| Ibsa Pharma INC. | $31.55 | 2024 | Tirosint, Licart |
| Otsuka America Pharmaceutical, INC. | $26.45 | 2024 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $26.38 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.29 | 2022 | |
| Mylan Specialty L.P. | $16.07 | 2023 | Yupelri |
| Daiichi Sankyo INC. | $15.89 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.26 | 2021 | |
| Indivior INC. | $11.67 | 2022 | |
| Amarin Pharma, INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Spohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.